Lab at McMaster University is one of only a handful in Canada that makes its own flu 

UNC’s Brian Strahl, PhD, and Van Andel Research Institute’s Scott Rothbart, PhD, create a robust online interactive database to address science’s ‘antibody crisis.’

Bacteria-specific molecules attract pre-existing antibodies to help immune system clear infection.

Antibodies are specific molecules that can lock onto a particular cellular structure to start, stop or otherwise temper a biological process. Because they are so specific, antibodies are at the forefront of drug discovery. So drug companies want a faster route to step one: identifying which of the millions of possible antibodies will work against molecules that cause disease.

Clinicians and patients alike know that traditional cancer treatments beat up the person as much as the cancer. Success arises only if the treatment kills the cancer before the patient. For decades, researchers sought solutions that attacked only the cancer, not healthy tissue.

Researchers have collaborated to craft a request that could fundamentally alter how the antibodies used in research are identified.

Nanobodies' promise hasn’t been fully realized, because scientists have lacked an efficient way of identifying the nanobodies most closely tuned to their targets

By imaging the immune response, researchers have observed how two types of immune cells, T and B cells, interact with one another during a critical period following infection

A new class of synthetic platelet-like particles could augment natural blood clotting for the emergency treatment of traumatic injuries – and potentially offer doctors a new option for curbing surgical bleeding and addressing certain blood clotting disorders without the need for transfusions of natural platelets.

Antibody therapy could fight second-most deadly strain of virus.

Laboratories at The Scripps Research Institute (TSRI) are investigating antibodies to fight Ebola virus, including the three antibodies recently used to treat two American health care workers infected with the Ebola virus.

Scientists at The Scripps Research Institute (TSRI) have demonstrated the power of a new drug discovery technique, which allows them to find—relatively quickly and cheaply—antibodies that have a desired effect on cells. The TSRI scientists used the technique to discover two antibodies that protect human cells from a cold virus.